Genmab A/S (GNMSF) Stock

About Genmab A/S

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malignancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL. Genmab further maintains approximately 20 active pre-clinical programs and a diverse array of compounds in Phase 2 development, investigating treatments for conditions like vaso-occlusive crises (Teclistamab), Hodgkin lymphoma and solid tumors (Camidanlumab tesirine), multiple myeloma (JNJ-64007957 and JNJ-64407564), celiac disease (PRV-015), hemophilia A (Mim8), and multiple system atrophy (Lu AF82422). The company engages in significant strategic collaborations, notably with Seagen Inc. for the co-development of tisotumab vedotin, CureVac AG for mRNA-based antibody products, and AbbVie for Epcoritamab, alongside other partnerships with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Genmab A/S is headquartered in DK.

Genmab A/S (GNMSF) stock trades at $285.85 with a market capitalization of $17.55B. The stock is valued at a price-to-earnings (P/E) ratio of 21.87, price-to-book of 3.14, price-to-sales of 1.90. Over the past 52 weeks the stock has ranged between $208.80 and $352.00, and currently trades 18.8% below its 52-week high.

On profitability, Genmab A/S generates a return on equity (ROE) of 14.55%, above the typical market average, return on capital employed of 11.49%, an operating margin of 13.65%, a net profit margin of 8.72%.

In its most recent fiscal year, Genmab A/S reported annual revenue of $3.9B, net profit of $997.0M, revenue has compounded at -17.6% a year over the last five years, profit at -26.8% a year.

The balance sheet shows a debt-to-equity ratio of 0.94, a current ratio of 2.18, total assets of $12.8B, $1.7B in cash and equivalents.

GNMSF has an average daily trading volume of 1,988 shares, a beta of 0.69 (less volatile than the overall market).

Official website: www.genmab.com